Search for stocks /

Rainbow Children’s Medicare Ltd Q1 FY26 (FY25): ₹353 Cr Sales, ₹53.5 Cr PAT, 56x P/E – Bacche ki jaan loge kya valuation se?


1. At a Glance

Rainbow is India’s largest pediatric hospital chain — 19 hospitals, 5 clinics, 1,935 beds, and 1,069,832 out-patient visits in FY25. Occupancy ~69%, ALOS just 2.9 days (baccha jaldi ghar chala jaata hai, bill jaldi ban jaata hai). Revenue grew 15% CAGR, profits 20% CAGR. Yet market says, “Bacchon ki hospital? Premium chaiye.” CMP ₹1,419 at P/E 56. Matlab patient se bhi zyada critical valuation ka ICU hai.


2. Introduction

Rainbow is not just a hospital chain — it’s the desi answer to “Let’s build Disneyland, but with stethoscopes.” Interiors are child-friendly, walls are painted like nursery, but bills are straight Apollo-style.

The model works: one-third of beds are ICU, and occupancy at 69% means beds are never really empty. With ₹2.93M revenue per occupied bed, every baby crying equals cash registers ringing.

But expansion spree is on steroids: Rajahmundry opened (100 beds), Guwahati acquired (Pratiksha Hospital, 76% stake), Warangal acquired (Prashanthi Hospital). Gurugram 300-bed hospital under development. Total bed target: 2,715.

So here’s the big roast: business is strong, numbers are fine, but valuation is richer than a Bandra pre-school charging ₹5 lakh donation for LKG admission.


3. Business Model – WTF Do They Even Do?

Rainbow = hub-and-spoke model.

  • Hubs: Hyderabad, Bengaluru, Chennai.
  • Spokes: Tier-II cities like Vizag, Vijayawada, Warangal.
  • Patients from spokes get referred to hubs.
  • Result: one big patient funnel, like McDonald’s Happy Meal but with IV drips.

Services offered:

  • NICU, PICU (neonatal & pediatric intensive care).
  • Pediatric subspecialties (nephrology, cardiology, oncology).
  • Organ transplants (serious quaternary care).
  • Women’s care under BirthRight by Rainbow.
  • Fertility care — IVF at 11 hospitals now.

So, RCML is not Apollo-level general hospital; it’s “baby + mummy” focused. Specialization = moat.


4. Financials Overview

Quarterly Comparison (₹ Cr)

MetricQ1 FY26 (Jun 25)Q1 FY25 (Jun 24)Q4 FY25 (Mar 25)YoY %QoQ %
Revenue353330370+7%-4.6%
EBITDA10494115+10.6%-9.6%
PAT53.54057+33.8%-6.1%
EPS (₹)5.273.895.55+35%-5%

Commentary: Sales growth muted, profits strong. Annualised EPS ~₹21. CMP ₹1,419 → P/E ~67. But screener shows 56, so somewhere between “over-expensive” and “kidney-selling expensive.”

👉 Reader poll: Would you pay ₹67 for ₹1 of profit if even the hospital charges ₹3 for Dettol swab?


5. Valuation Discussion – Fair Value Range

Method 1: P/E
EPS TTM = ₹25.4.
Assign fair multiple = 30–40x (sector avg 45–70, but Rainbow niche).
Fair Value = ₹760 – ₹1,020.

Method 2: EV/EBITDA
EV = ₹15,155 Cr. EBITDA FY25 = ₹500 Cr. EV/EBITDA = 30x.

Join 10,000+ investors who read this every week.
Become a member
error: Content is protected !!